Gelesis raises $30 million to fund novel weight loss therapy

1 March 2018
money_big-1

Boston, USA-based Gelesis has raised $30 million to support development of its pipeline of gastrointestinal disorder therapies, which includes candidates targeting type 2 diabetes and non-alcoholic steatohepatitis (NASH).

The company, which is an affiliate of the UK's PureTech Health (LSE: PRTC), is using mechanotherapeutics, an approach which leverages physical forces or mechanical signaling pathways as part of a product’s mechanism of action.

The money will be used to support commercial-stage manufacturing, product launch preparations, company operations, and clinical advancement.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical